297 related articles for article (PubMed ID: 21592450)
1. Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Raju N; Sobieraj-Teague M; Hirsh J; O'Donnell M; Eikelboom J
Am J Med; 2011 Jul; 124(7):621-9. PubMed ID: 21592450
[TBL] [Abstract][Full Text] [Related]
2. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
3. Aspirin for Primary Prevention of Cardiovascular Events.
Abdelaziz HK; Saad M; Pothineni NVK; Megaly M; Potluri R; Saleh M; Kon DLC; Roberts DH; Bhatt DL; Aronow HD; Abbott JD; Mehta JL
J Am Coll Cardiol; 2019 Jun; 73(23):2915-2929. PubMed ID: 31196447
[TBL] [Abstract][Full Text] [Related]
4. Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
Wang M; Yu H; Li Z; Gong D; Liu X
Am J Cardiovasc Drugs; 2022 Nov; 22(6):657-675. PubMed ID: 35570250
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
Gelbenegger G; Postula M; Pecen L; Halvorsen S; Lesiak M; Schoergenhofer C; Jilma B; Hengstenberg C; Siller-Matula JM
BMC Med; 2019 Nov; 17(1):198. PubMed ID: 31679516
[TBL] [Abstract][Full Text] [Related]
6. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Butalia S; Leung AA; Ghali WA; Rabi DM
Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
[TBL] [Abstract][Full Text] [Related]
7. A comparison of contemporary versus older studies of aspirin for primary prevention.
Moriarty F; Ebell MH
Fam Pract; 2020 Jul; 37(3):290-296. PubMed ID: 31751455
[TBL] [Abstract][Full Text] [Related]
8. Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease.
Cleland JG
Am J Med; 2012 Feb; 125(2):e13. PubMed ID: 22269629
[No Abstract] [Full Text] [Related]
9. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet agents for intermittent claudication.
Wong PF; Chong LY; Mikhailidis DP; Robless P; Stansby G
Cochrane Database Syst Rev; 2011 Nov; (11):CD001272. PubMed ID: 22071801
[TBL] [Abstract][Full Text] [Related]
11. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Kunutsor SK; Seidu S; Khunti K
Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
[TBL] [Abstract][Full Text] [Related]
12. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
[TBL] [Abstract][Full Text] [Related]
13. P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.
Li ZX; Xiong Y; Gu HQ; Fisher M; Xian Y; Johnston SC; Wang YJ
Stroke; 2021 Jul; 52(7):2250-2257. PubMed ID: 34039032
[TBL] [Abstract][Full Text] [Related]
14. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
[TBL] [Abstract][Full Text] [Related]
15. The role of aspirin in primary prevention of vascular events.
Badri M; Saeed W; Sardar MR
Am J Med; 2012 Dec; 125(12):e11. PubMed ID: 23164487
[No Abstract] [Full Text] [Related]
16. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
Joseph P; Roshandel G; Gao P; Pais P; Lonn E; Xavier D; Avezum A; Zhu J; Liu L; Sliwa K; Gamra H; Bangdiwala SI; Teo K; Diaz R; Dans A; Lopez-Jaramillo P; Prabhakaran D; Castellano JM; Fuster V; Rodgers A; Huffman MD; Bosch J; Dagenais GR; Malekzadeh R; Yusuf S;
Lancet; 2021 Sep; 398(10306):1133-1146. PubMed ID: 34469765
[TBL] [Abstract][Full Text] [Related]
17. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
McGrath E; O'Conghaile A; Eikelboom JW; Dinneen SF; Oczkowski C; O'Donnell MJ
Cerebrovasc Dis; 2011; 32(1):22-7. PubMed ID: 21576939
[TBL] [Abstract][Full Text] [Related]
18. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
